PBAC's latest decision on Vismodegib: Recommended with restriction (2017). Considered for Metastatic or locally advanced basal cell carcinoma that is inappropriate for surgery and inappropriate for curative radiotherapy.
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
Not modelled
no economic evaluation
Submissions
3
first 2016
Submissions
3
2016 → 2017
Eligible population
Patients with metastatic or locally advanced basal cell carcinoma for whom curative resection and curative radiotherapy are inappropriate.
Therapy area
Oncology
Line of therapy
Any
Evidence base
Other
Economic model
Not modelled
ICER note
Not modelled — this is a minor submission to relax restrictions on an existing listing, not a new economic evaluation.
ICER (historical)
$45k/QALY–$75k/QALY in an earlier submission (2016) — the latest submission carried no numeric base case. No single PSD states this combined range; see source PSDs.
Submission history
Mar 2016: Recommended with restriction · Authority Required
Nov 2016: Recommended with restriction · Authority Required — ICER $75k/QALY
Nov 2017: Recommended with restriction · Authority Required